SBBP Key Statistics, Chart & Performance
The current stock price of SBBP is 2 null. In the past month the price decreased by -8.68%. In the past year, price decreased by -11.5%.
SBBP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.98 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20.02 | 500.60B | ||
| MRK | MERCK & CO. INC. | 12.08 | 264.21B | ||
| PFE | PFIZER INC | 7.82 | 142.31B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.34 | 111.38B | ||
| ZTS | ZOETIS INC | 19.79 | 55.30B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.55 | 22.66B | ||
| VTRS | VIATRIS INC | 5.25 | 14.10B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.31 | 11.12B | ||
| CORT | CORCEPT THERAPEUTICS INC | 94.99 | 8.79B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.74B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About SBBP
Company Profile
Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. The company is headquartered in Trevose, Pennsylvania and currently employs 72 full-time employees. The company went IPO on 2015-09-10. The firm is focused on the development and commercialization of therapies for a range of diseases. The firm's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The firm has a clinical-stage pipeline of therapies for endocrine diseases. The firm's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The firm is studying COR-003 for the treatment of endogenous Cushing's syndrome. The company is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
Company Info
Strongbridge Bio Ord
900 Northbrook Dr Ste 200
Trevose PENNSYLVANIA 19053 US
CEO: John H. Johnson
Employees: 72
Phone: 16102549200.0
Strongbridge Bio Ord / SBBP FAQ
What does SBBP do?
Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. The company is headquartered in Trevose, Pennsylvania and currently employs 72 full-time employees. The company went IPO on 2015-09-10. The firm is focused on the development and commercialization of therapies for a range of diseases. The firm's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The firm has a clinical-stage pipeline of therapies for endocrine diseases. The firm's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The firm is studying COR-003 for the treatment of endogenous Cushing's syndrome. The company is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
What is the current price of SBBP stock?
The current stock price of SBBP is 2 null. The price increased by 1.52% in the last trading session.
Does Strongbridge Bio Ord pay dividends?
SBBP does not pay a dividend.
What is the ChartMill rating of Strongbridge Bio Ord stock?
SBBP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists SBBP stock?
SBBP stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of SBBP stock?
Strongbridge Bio Ord (SBBP) operates in the Health Care sector and the Pharmaceuticals industry.
What is the Price/Earnings (PE) ratio of Strongbridge Bio Ord (SBBP)?
Strongbridge Bio Ord (SBBP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.41).
SBBP Technical Analysis
SBBP Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SBBP. SBBP has a bad profitability rating. Also its financial health evaluation is rather negative.
SBBP Financial Highlights
Over the last trailing twelve months SBBP reported a non-GAAP Earnings per Share(EPS) of -0.41. The EPS increased by 49.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -115.66% | ||
| ROA | -41.48% | ||
| ROE | N/A | ||
| Debt/Equity | 0.38 |
SBBP Forecast & Estimates
4 analysts have analysed SBBP and the average price target is 5.1 null. This implies a price increase of 155% is expected in the next year compared to the current price of 2.
For the next year, analysts expect an EPS growth of 35.78% and a revenue growth 25.01% for SBBP